Clinical Research Directory

Inclusion Criteria: * Aged 18 years or older at the time of signing the informed consent form * Diagnosed with PIK3CA-mutated, hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer. * Confirmed PIK3CA mutation status in blood or tumor tissue using NMPA-approved or adequately validated testing methods (PCR or NGS) prior to initiating inavolisib therapy. * First-time recipient of inavolisib treatment. * The study center can provide complete electronic medical records, prescription records, and laboratory test data. Exclusion Criteria: * Concomitant history of recent severe metabolic disorders, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state. * Prior participation in any clinical trial where adverse events experienced during that trial have not resolved or stabilized prior to starting inavolisib (as determined by the investigator). * Currently participating in any other clinical study or trial that prohibits concurrent participation in this study. * Any condition or reason that, in the opinion of the investigator, makes the patient unsuitable for study participation or difficult to follow up.